Drug Abuse Science Gets Partial Public Peep Show
Published Date: 3/25/2025
Notice
Summary
The National Institute on Drug Abuse is holding a virtual meeting on May 13, 2025, to review grant applications and discuss important drug research topics. This meeting affects researchers and organizations seeking funding, with some parts open to the public and others private to protect sensitive info. No direct money changes are announced, but grant decisions could impact future funding.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
NIDA Will Review Grant Applications
On May 13, 2025, the National Advisory Council on Drug Abuse will meet virtually to review and evaluate grant applications (closed session 11:00 a.m. to 12:15 p.m.). This meeting directly concerns researchers and organizations that have submitted grant applications to the Institute.
Open Session Videocast for Public Viewing
The Council's open session on May 13, 2025, from 1:30 p.m. to 5:00 p.m. will be videocast and can be accessed from the NIH Videocasting and Podcasting website. Anyone may view the presentations and business of the Council via that videocast.
Portion Closed to Protect Confidential Information
A portion of the May 13, 2025 meeting (11:00 a.m. to 12:15 p.m.) will be closed to the public under 5 U.S.C. 552b(c)(4) and (c)(6) to protect confidential trade secrets, commercial property, patentable material, and personal information tied to grant applications. That closed review applies to applicants whose materials could disclose confidential or personally sensitive information.
Anyone May File Written Comments
Any interested person may file written comments for the committee by emailing Dr. Gillian Acca; comments should include name, address, telephone number, and, when applicable, business or professional affiliation. The notice provides a clear, open channel for public input to the Council.
Accessibility Accommodations Available by Request
Individuals who plan to view the virtual meeting and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify Dr. Gillian Acca by email five days before the May 13, 2025 meeting. The Institute provides a process to request accommodations for the videocast.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2025-04980, National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on May 1, 2025, to review grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. No public access or money changes are involved, but the review helps decide who gets research support.
Next: 2025-04982, Certain Active Matrix Organic Light-Emitting Diode Display Panels and Modules for Mobile Devices, and Components Thereof; Notice of the Commission's Final Determination Finding No Violation of Section 337; Termination of the Investigation
The U.S. International Trade Commission looked into certain OLED display panels and parts used in mobile devices and found no rule-breaking. This means the investigation is over, and companies can keep making and selling these products without worry. No fines or penalties are coming, so business stays smooth and steady.